Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Seres Therapeutics, Inc. (MCRB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/08/2023 8-K Quarterly results
Docs: "Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates"
05/09/2023 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates",
"Seres Therapeutics, Inc. Corporate Presentation as of May 2023",
"Seres Therapeutics, Inc. SER-155 Phase 1b Cohort 1 Study Results Slide Presentation as of May 2023",
"Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome"
04/27/2023 8-K Quarterly results
03/07/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates"
01/09/2023 8-K Investor presentation
Docs: "Seres Therapeutics, Inc. Corporate Presentation as of January 2023",
"Seres Therapeutics, Inc. Corporate Presentation as of January 2023"
01/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/14/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates"
06/30/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates"
04/06/2022 8-K Investor presentation
Docs: "Seres Therapeutics, Inc. Corporate Presentation as of April 6, 2022"
03/01/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates"
08/03/2021 8-K Quarterly results
Docs: "Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates"
07/22/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis"
07/01/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/21/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/07/2020 8-K Termination of a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Fin...
Docs: "Amended and Restated Bylaws of Seres Therapeutics, Inc",
"Amended and Restated Bylaws of Seres Therapeutics, Inc"
11/20/2020 8-K Investor presentation
Docs: "Seres Therapeutics, Inc. Corporate Slide Presentation as of November 20, 2020"
08/14/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
06/22/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/23/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of the Securities Exchange Act of 1934 Date of report : March 20, 2020 SERES THERAPEUTICS, INC. Delaware 001-37465 27-4326290 200 Sidney Street Cambridge, MA 02139 Registrant's telephone number, including area code: 945-9626 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commence..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy